



Aalborg Universitet

AALBORG UNIVERSITY
DENMARK

Validation of Updated Diagnostic Criteria

IDH-Wildtype Diffuse Astrocytoma with Molecular Features of Glioblastoma

Stubbe, Benjamin Emil; Holmsgaard Eskesen, Mathias; Haslund, Charlotte Aaquist; Carus, Andreas; Ettrup, Marianne Schmidt; Delekta, Agnieszka Monika ; Poulsen, Laurids Østergaard

Creative Commons License
Unspecified

Publication date:
2021

Document Version
Publisher's PDF, also known as Version of record

[Link to publication from Aalborg University](#)

Citation for published version (APA):

Stubbe, B. E., Holmsgaard Eskesen, M., Haslund, C. A., Carus, A., Ettrup, M. S., Delekta, A. M., & Poulsen, L. Ø. (2021). *Validation of Updated Diagnostic Criteria: IDH-Wildtype Diffuse Astrocytoma with Molecular Features of Glioblastoma*. Poster presented at Danske Kræftforskningsdage 2021, Odense, Denmark.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

INTRODUCTION

According to updated diagnostic criteria, diffuse astrocytic gliomas (DA), WHO grade II-III, isocitrate dehydrogenase wildtype (IDHwt) which expresses at least one of the three following:

- EGFR amplification**
- TERT promoter mutation**
- Combined whole chromosome 7 gain and whole chromosome 10 loss**

should exhibit a more aggressive clinical course, resembling glioblastoma WHO grade IV.

AIM

To validate the updated diagnostic criteria.

METHODS

Who?

Patients diagnosed with DA, WHO grade II, in 2004-2018, at Aalborg University Hospital.

How?

Next Generation Sequencing, immunohistochemistry and FISH were used to analyze tumour samples.

CONCLUSION

Due to a limited sample size, the updated diagnostic criteria could not be validated. However, the molecular criteria predicted a significantly poorer survival independent of IDH-status. Thus, the results support the new treatment guideline in which patients meeting the updated diagnostic criteria should be treated as patients with glioblastoma.



Mathias Holmsgaard Eskesen

MD, m.eskesen@rn.dk
Department of Oncology,
Aalborg University Hospital, Denmark

Authors:


*Stubbe, B.E.; Eskesen, M.H.; Haslund, C.A.;
Carus, A.; Ettrup, M.S.; Delekta, A.; Poulsen, L.Ø.*



Benjamin Emil Stubbe

MD, Ph.D. student, b.stubbe@rn.dk
Department of Surgery,
Aalborg University Hospital, Denmark

RESULTS



Cumulative survival probability according to time in years

